This website is for Israeli Healthcare Professionals only


UBRELVY is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. UBRELVY is not indicated for the preventive treatment of migraine.1


QULIPTA is indicated for the preventive treatment of episodic migraine in adults.2


Botox is indicated for symptom relief in adults fulfilling criteria for chronic migraine (headaches on ≥15 days per month of which at least 8 days with migraine) in patients who have responded inadequately or are intolerant of prophylactic migraine medications.3

For full information please see  prescribing/product information.

Full prescribing information can be recieved from AbbVie Biopharmaceuticals Ltd. Israel at Hacharash street, Hod Hasharon 4524075.

Tel: 09-7907600, Fax: 09-7909606.


  1. Ubrelvy Israel Prescribing information, July 2022
  2. Qulipta Israel Prescribing information, Sep 2022
  3. Botox Israel Prescribing information, Nov 2022


IL-UBR-230016 / FEB 2023